Kiniksa Pharmaceuticals International, plc
KNSA
Rangering i aksjer
#2917
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aksjekurs
$80.10
Sist synkronisert: 2026-10-21
Markedsverdi
$6.25B
Endring (1 dag)
-3.69%
Endring (1 år)
105.92%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Aksjeprishistorikk for Kiniksa Pharmaceuticals International, plc (KNSA)
Høyeste sluttskurs: $78.59 den 2026-10-01
Laveste sluttskurs: $18.08 den 2018-05-01
Laveste sluttskurs: $18.08 den 2018-05-01
Aksjeprishistorikk for Kiniksa Pharmaceuticals International, plc fra 2018 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 31.83% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.29 | 34.87% |
SE
|
|
| $170.92 | 23.58% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
